In summary, we provide evidence of beneficial effects of Tonabersat in blocking Cx43 hemichannel-mediated ATP release in an in vitro model of human DN, negating downstream NLRP3 priming/activation, macrophage polarisation/motility and tubule cell/macrophage expression of pro-inflammatory mediators. The gene discussed is GJA1; the disease is liver dysplastic nodule.